18 and older, any sex, with Depressive Symptoms or Depression. Patients with the condition only — healthy volunteers not accepted.
Results — posted to ClinicalTrials.gov
Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.
Mean Score of Depressive SymptomsPrimary· Between baseline and week 12
Patients will self report depressive symptoms weekly for 8 weeks with final follow-up at 12-weeks via the Beck Depression Inventory-II. The range of scores possible are 0 - 63, where lower scores are indicative of lower symptoms of depression.
Group
Value
95% CI
Group A- Treatment as Usual
-5.95
± 11.61
Group B- Moodivate
-11.24
± 11.67
Group C- Moodivate + EHR
-10.69
± 12.87
Sponsor's own description
The purpose of this research study is to evaluate a mobile application (app) for depression treatment. Participants will be randomly assigned to either receive the mobile app, "Moodivate", or not. If provided with Moodivate, participants will be asked to use the app regularly, at least once per day, throughout the study duration. Participants will be asked to complete electronic questionnaire measures throughout the study period. Participation in this study will take about 12 weeks.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
NCT05932810 — Evaluation of a Proactive Identification and Digital Mental Health Intervention Approach to Address Unmet Psychosocial N
· NA
· completed
NCT04951193 — Goal2QuitVaping for Nicotine Vaping Cessation Among Adolescents
· NA
· completed
Other recruiting trials for Depressive Symptoms
Currently open trials in the same condition.
NCT07299903 — IMB-Based Sleep Hygiene Education for Menopausal Women: Effects on Sleep Quality and Depression
· NA
· recruiting
NCT07413692 — BTL-699-2 and HPM-6000UF Devices for the Improvement of Depressive Symptoms and Urinary Incontinence in Postpartum and E
· NA
· recruiting
NCT07413705 — BTL-699-2 and HPM-6000UF Devices for the Improvement of Depressive Symptoms and Sexual Function Among Perimenopausal and
· NA
· recruiting
NCT07241325 — Psychological Well-Being, Depression, and Health-Related Quality of Life in Adults With Type 2 Diabetes: A Cross-Section
· recruiting
NCT07216326 — Our Voices Matter: Intervention for Depression in Youth
· NA
· recruiting
Other Medical University of South Carolina trials
Trials by the same sponsor.
NCT06491264 — Multiparameter Optimized tES for Memory in Aging
· NA
· withdrawn
NCT07513389 — Omission of Postoperative Radiation in HPV-Associated Oropharyngeal Cancer Using ctHPVDNA Surveillance (OPERATION)
· Phase 2
· not yet recruiting
NCT03101917 — Microtable® Method for Cochlear Implantation Investigational Device Exemption (IDE)
· NA
· not yet recruiting
NCT07149207 — Intraoperative Molecular Imaging Using ICG for Head and Neck Tumors
· Phase 2
· recruiting
NCT06148038 — CBD for Breast Cancer Primary Tumors
· Phase 1
· recruiting
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Medical University of South Carolina
Last refreshed: 19 November 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04463914.